Valneva starts PhII C. diff trial; EC backs Ebola vaccine consortium for GSK candidate;

> Valneva has kicked off a Phase II trial of its Clostridium difficile vaccine. Report

> The European Commission (EC) has put €15.1 million behind a consortium of leading research institutions devoted to advancing development of GlaxoSmithKline's Ebola vaccine candidate. More

> Seattle researchers have discovered a vaccine candidate that they expect to stimulate the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains. Release

> The U.S. Patent and Trademark Office has issued key protection for ImmunoCellular Therapeutics' glioblastoma vaccine. Release

And Finally... A mumps outbreak that has so far affected 15 NHL players on 5 teams "could happen anywhere," experts say. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.